IL-2 fusion protein PTX-912
Term · Oncology and biomedicine · MLC-T-ONC-014356
A fusion protein consisting of the cytokine interleukin-2 (IL-2) fused to an as of yet not fully elucidated protein, with potential immunopotentiating and antineoplastic activities. Upon administration, IL-2 fusion protein PTX-912 targets and binds to IL-2 receptors, and activates IL-2 receptor-mediated signaling in immune cells. This activates cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells, and induces expression of certain cytotoxic cytokines, such as interferon-gamma (IFNg) and transforming growth factor-beta (TGFb). This leads to T-cell-mediated cytotoxic immune responses against tumor cells and inhibits tumor cell proliferation.
| Identifier | MLC-T-ONC-014356 |
|---|---|
| Field | Oncology and biomedicine |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-014356",
"term": "IL-2 fusion protein PTX-912",
"field": "Oncology and biomedicine",
"definition": "A fusion protein consisting of the cytokine interleukin-2 (IL-2) fused to an as of yet not fully elucidated protein, with potential immunopotentiating and antineoplastic activities. Upon administration, IL-2 fusion protein PTX-912 targets and binds to IL-2 receptors, and activates IL-2 receptor-mediated signaling in immune cells. This activates cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells, and induces expression of certain cytotoxic cytokines, such as interferon-gamma (IFNg) and transforming growth factor-beta (TGFb). This leads to T-cell-mediated cytotoxic immune responses against tumor cells and inhibits tumor cell proliferation.",
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/il-2-fusion-protein-ptx-912/"
}
Record 9,007 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.